Available Trials

Main Content

Neurological and Brain Cancers

For more information regarding these studies, contact Cancer Research and Registry at (601) 984-1095.



A071401: Phase II Trial Of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations Temporarily closed to accrual

The purpose of this study is to test good and bad effects of two different drugs, vismodegib and GSK2256098, against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients, and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in meningioma and have found several genes that are altered, or mutated. These include the genes called SMO and NF2. When the SMO or NF2 genes are altered, it can cause a tumor to grow. There are medications that target these 2 genes.

The medication, vismodegib, blocks the SMO receptor. Vismodegib has already been FDA-approved to treat basal cell cancer, which is a type of skin cancer.

The medication, GSK2256098, blocks FAK, and seems to work better in tumors that have NF2-mutations. GSK2256098 has been tested in other cancers.

Principal Investigator: Barbara Craft, MD

Brain Metastases from NSCLC

METIS EF-25: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).

The purpose of this study is to obtain information on the safety and effectiveness of NovoTTF-100M (study device) in participants with brain metastases (tumors) as a result of non-small cell lung cancer.

Radiosurgery (SRS) is commonly used as a treatment for brain metastases (tumors) and is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to a small spot in the brain (your tumor) while excluding the surrounding normal brain from the radiation.

Principal Investigator: Mark Anderson, MD